Novartis AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVS research report →
About the company
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
- CEO
- Vas Narasimhan
- IPO
- 1996
- Employees
- 75,511
- HQ
- Basel, BS, CH
Price Chart
- Market Cap
- $305.10B
- P/E
- 22.82
- P/S
- 5.48
- P/B
- 7.87
- EV/EBITDA
- 15.44
- Div Yield
- 2.89%
- Gross Margin
- 75.13%
- Op Margin
- 29.88%
- Net Margin
- 24.31%
- ROE
- 31.54%
- ROIC
- 14.89%
- Revenue
- $54.81B · 5.97%
- Net Income
- $14.06B · 17.71%
- EPS
- $7.25 · 22.47%
- Op Income
- $17.07B
- FCF YoY
- 28.11%
- 52W High
- $170.46
- 52W Low
- $112.34
- 50D MA
- $149.43
- 200D MA
- $143.49
- Beta
- 0.49
- Avg Volume
- 1.71M
Get TickerSpark's AI analysis on NVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NVS coverage
Recent articles, reports, and earnings notes.
Eli Lilly is turning obesity demand into an access story now
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.
Merck’s latest data may have bought it more time than bears want to admit
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Want a deeper read on NVS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.